• Quick Order
  • Careers
  • Support
Breast cancer cells Credit Annie Cavanagh.jpg

AACR Annual Meeting 2024

San Diego Convention Center, San Diego, California

April 05, 2024 - April 10, 2024

We are delighted that we were able to connect with so many scientists at the 2024 AACR Annual Meeting. While the event may have ended, your cutting-edge research has not! Check out our poster presentations from the event and explore our resources for cancer diagnostics and drug development below to see how we can support your oncology and immuno-oncology studies.

Did you miss us at booth #1413 and would like to speak to one of ATCC’s representatives about a product or service? Contact us so we can discuss your needs.

Contact us

Check out our poster presentations

Luciferase reporter cell lines allow simultaneous incorporation of tumor cells, innate immune cells, and adaptive immune cells for in-depth immune checkpoint studies
Presenter: Hyeyoun Chang, PhD, Scientist, ATCC
Date: Sunday, April 7, 2024
Time: 1:30 PM – 5:00 PM
Abstract number: 75

Get the poster

Pancreatic cancer organoids from the Human Cancer Models Initiative biobank reflect disease genotypes, capture patient heterogeneity, and are amenable to therapeutic screening
Presenter: Stephen Friend, MS, Biologist, ATCC
Date: Tuesday, April 9, 2024
Time: 9:00 AM – 12:30 PM
Abstract number: 4239

Get the poster

Meet the presenters

Hyeyoun Chang, headshot

Hyeyoun Chang, PhD

Scientist, ATCC

Hyeyoun Chang, PhD, is a Scientist in the Immuno-oncology group of the R&D department at ATCC. She has extensive experience in the fields of biomedical engineering and cancer biology that focuses on drug delivery, intracellular signaling, and gene therapy. Prior to joining ATCC, Dr. Chang received her PhD in biomedical engineering from Korea University of Science and Technology and completed her postdoctoral training at Dana-Farber Cancer Institute/ Harvard Medical School. 

Stephen Friend.jpg

Stephen Friend, MS

Biologist, ATCC

Stephen Friend is a Biologist in the Microphysiological Systems group of the R&D department at ATCC. He started his scientific career at ATCC three years ago after receiving his Master’s Degree in Biomedical Science from Hood College. Stephen has worked on a variety of projects at ATCC including primary cell and cancer cell line culture, airway modeling and optimization using air-liquid-interface techniques, and the development and production of 3D patient-derived cancer organoids from various primary tissues.

Cancer immunotherapy white oral squamous red cytotoxic T-cells

Human Cancer Models Initiative

ATCC is collaborating with the Human Cancer Models Initiative (HCMI) to offer scientists a wide variety of next-generation 2-D and 3-D patient-derived in vitro cancer models, including organoids.

ATCC is committed to making available a growing collection of models generated by the HCMI, which will include both common as well as rare and understudied examples of cancer from numerous tissues. These HCMI models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research.

Find next-generation models

Download a PDF of our featured literature

Immune checkpoint inhibitors: Interaction between PD-1 (blue) on a T-cell and PD-L1 (red) on a cancer cell blocked by therapeutic antibodies Brochure

Immuno-oncology Capabilities

ATCC provides a large collection of fully characterized and authenticated cell lines, human primary cells, and advanced cell models such as checkpoint luciferase reporter cells and CAR-T target luciferase reporter cells that support immuno-oncology therapeutic development.

Pipette filling a well-plate with pink media Application note

Development and performance evaluation of a modified xeno-free McCoy's 5A medium formulation: McCoy’s 5A Medium, ABP-Free (ATCC 30-2011)

Our newly developed animal by-product free McCoy’s 5A medium was tested across several ATCC cell lines for performance and was found to be a suitable substitute for the current McCoy’s 5A Medium.

NIH3T3.2_typical monolayer, no foci_Stained_Day21.jpg Application note

A Novel NIH/3T3 Clonal Derivative: NIH/3T3.2 Re-Developed as a Cell Model for Contact Inhibition Research

This study showcases the development of a NIH/3T3 clonal derivative that maintains the contact inhibition property associated with this cell line.

immune checkpoint inhibitor Brochure

Checkpoint Luciferase Reporter Cells

To facilitate large-scale drug discovery of immune checkpoint inhibitors, ATCC created tumor and immune cell lines with high endogenous expression of checkpoint inhibitory and co-stimulatory expression levels.

CAR-T cells, CAR-Target, CD19, CD20, HER2 Brochure

CAR-T Target Luciferase Reporter Cells

ATCC generated CAR-T Target Luciferase Reporter Cells lines that have high endogenous expression of clinically relevant cell surface tumor antigens, such as CD19, CD20, and HER2. These new immuno-oncology tools are comprised of both solid and liquid tumor cell lines that exhibit sensitive and stable luciferase reporter expression.

Green and blue NuLi lung epithelial small airway cells. Brochure

hTERT-immortalized Primary Cells

Enjoy the best of all worlds with human telomerase reverse transcriptase (hTERT)-immortalized Primary Cells from ATCC.

CAR-T cells, CAR-Target, CD19, CD20, HER2 Application note

Luciferase Reporter Cancer Cell Lines Facilitate CAR-T Development

This report describes ATCC luciferase reporter solid and liquid tumor cell lines that express tumor antigens such as CD19, CD20, and HER2. Learn how you can incorporate these target cells into your T-Cell cytotoxicity assays to enable your breakthroughs in immuno-oncology.

Blue and black cells. Brochure

Cell Lines by Gene Mutation

This guide organizes our ATCC tumor cell lines according to gene of interest and provides information for each line about the specific mutation.

Gloved hand holding metal pointer over DNA sequence on digital display screen. Brochure

Genetic Alteration Cell Panel

A comprehensive guide providing details and data on our AKT, BRAF, EGFR, ERK, FGFR, MET, MYC, PI3K, PTEN, and RAS genetic alteration cell panels.

A bright-blue, fluorescent, DAPI stain sphere with a black background. Brochure

Isogenic Cell Lines

With genome editing tools such as CRISPR/Cas9, ATCC has created isogenic cell lines with mutants of key oncogenes, which are ideal for identifying novel, personalized treatment regimens. Explore our resources.

Pink and red HGF atubulin 2 hepatocyte line. Brochure

Tumor/Normal Matched Cell Line Pairs

Tumor-derived cell lines matched to either normal or metastatic cell lines obtained from the same patient provide a valuable resource for cancer studies.

Pipette filling a well-plate with pink media Brochure

High Performance Media, Sera, and Reagents

Using ATCC high-performance media, sera, and reagents will ensure robust, continuous cell growth, consistent performance, and minimum cell loss when reviving cells from cryopreservation.


Contact us today

Your ATCC sales representative stands ready to discuss your research needs and provide you with personalized care. Please complete our form to let us know how we can help, and we will start working on your needs right away.

We will not share your information outside of our distributors network and solely use it to send relevant communications.
Your form was successfully submitted